Ignite Creation Date:
2025-12-24 @ 11:15 PM
Ignite Modification Date:
2026-04-02 @ 7:15 AM
Study NCT ID:
NCT01232556
Status:
TERMINATED
Last Update Posted:
2019-01-08
First Post:
2010-10-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Sponsor:
Pfizer
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
B1931008
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |